British Columbia-based marijuana producer Tilray Inc. has filed for an initial public offering on the Nasdaq stock exchange.

The company said in a release it has filed with the U.S. Securities and Exchange Commission for a proposed IPO to list its Class 2 common stock on the Nasdaq under the ticker symbol “TLRY.”

Tilray said the number of shares it will offer and the price range have not been determined yet.

BMO Capital Markets and New York-based investment bank Cowen and Co. will jointly act as book-runners for the proposed listing, the release said.

In its regulatory filing, Tilray reported 2017 revenue of about $20.54 million, up more than 38 per cent from $12.64 million a year earlier. The company’s net loss was $7.81 million in 2017, down slightly from $7.88 million in 2016.

The company says it does not intend to list on any stock exchange in Canada.

In its filing, Tilray boasts of having its products available in 10 countries and agreements with established pharmaceutical distributors in 12.

In Canada, the company has signed agreements to supply medical cannabis to Pharmasave and Shoppers Drug Mart.

The company has also signed agreements to supply cannabis for adult-use with Quebec, Yukon, and the Northwest Territories and says it's finalizing a letter of intent with Manitoba.

With files from The Canadian Press